Interestingly, while IL-6 levels declined after twelve months, other inflammatory markers remained stable, highlighting IL-6 as a potential biomarker for monitoring the clinical status of LC patients [17]. The gene discussed is IL6; the disease is laryngotracheoesophageal cleft.